To further characterize RBM17 in AML patient cells, we analyzed its expression in the TCGA-LAML (https://portal.gdc.cancer.gov/projects/TCGA-LAML) and BeatAML datasets and found that RBM17 expression was significantly higher in both poor/adverse and intermediate molecular genetic risk groups compared with the good/favorable molecular genetic risk group (Fig. 1f, g). Here, RBM17 is linked to acute myeloid leukemia.